Status:
COMPLETED
Evaluation of Subcutaneous Immunotherapy Towards Pollen in Children
Lead Sponsor:
Karolinska Institutet
Conditions:
Rhinitis, Allergic
Conjunctivitis, Allergic
Eligibility:
All Genders
6-18 years
Phase:
NA
Brief Summary
The objective is to prospectively explore associations between immunological parameters in blood and clinical effect of subcutaneous immunotherapy (SCIT) in children with severe allergy towards pollen...
Detailed Description
Before start of SCIT, with Alutard pollenextract/s from " Allergologisk Laboratorium Köbenhavn" (ALK), and after one year of treatment, immunoglobulin E (IgE)-antibody levels towards the crude allerge...
Eligibility Criteria
Inclusion
- Seasonal Rhinoconjunctivitis caused by grass and/or birch pollen allergy
- Insufficient clinical effect of symptomatic treatment (antihistamine, nasal corticosteroids)
- IgE antibodies to grass and/or birch pollen antigens
Exclusion
- severe comorbidity, severe asthma, pregnancy
Key Trial Info
Start Date :
May 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03375775
Start Date
May 1 2017
End Date
January 31 2022
Last Update
April 5 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Karolinska University Hospital
Stockholm, Sweden